BRY812 for injection

DRUG2 trials

Sponsors

BioRay Pharmaceutical Co., Ltd.

Conditions

Advanced Gynecological MalignanciesAdvanced Malignancies

Phase 1

A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

RecruitingNCT06038058

BioRay Pharmaceutical Co., Ltd.Advanced Malignancies

Start: 2023-10-10End: 2028-12-31Target: 164Updated: 2025-12-30

Phase 2

Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies

Not yet recruitingNCT07311538

BioRay Pharmaceutical Co., Ltd.Advanced Gynecological Malignancies

Start: 2025-12-31End: 2028-11-30Target: 56Updated: 2025-12-31

Related Papers

Association of LIV-1 expression with clinical efficacy in patients with advanced breast cancers treated with BRY812.

Journal of Clinical Oncology2025-05-28

The safety, tolerability, and efficacy of BRY812 in patients with advanced solid tumors: Preliminary results from the phase I clinical study.

Journal of Clinical Oncology2025-05-28